These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 27063471)

  • 21. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
    Chan AM; Enwere E; McIntyre JB; Wilson H; Nwaroh C; Wiebe N; Ou Y; Liu S; Wiedemeyer K; Rambau PF; Grevers X; Morris DG; Neri P; Gilks CB; Visser F; Le N; Luo L; Cook LS; Köbel M
    J Pathol Clin Res; 2020 Oct; 6(4):252-262. PubMed ID: 32391646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extracellular microRNA profiling for prognostic prediction in patients with high-grade serous ovarian carcinoma.
    Yoshida K; Yokoi A; Matsuzaki J; Kato T; Ochiya T; Kajiyama H; Yamamoto Y
    Cancer Sci; 2021 Dec; 112(12):4977-4986. PubMed ID: 34618992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
    Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
    JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathological and prognostic implications of the miR-200 family in patients with epithelial ovarian cancer.
    Cao Q; Lu K; Dai S; Hu Y; Fan W
    Int J Clin Exp Pathol; 2014; 7(5):2392-401. PubMed ID: 24966949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hsp70 (HSPA1) Lysine Methylation Status as a Potential Prognostic Factor in Metastatic High-Grade Serous Carcinoma.
    Jakobsson ME; Moen A; Davidson B; Falnes PØ
    PLoS One; 2015; 10(10):e0140168. PubMed ID: 26448330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exosome-derived miRNAs and ovarian carcinoma progression.
    Vaksman O; Tropé C; Davidson B; Reich R
    Carcinogenesis; 2014 Sep; 35(9):2113-20. PubMed ID: 24925027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased expression of microRNA-196a predicts poor prognosis in human ovarian carcinoma.
    Fan Y; Fan J; Huang L; Ye M; Huang Z; Wang Y; Li Q; Huang J
    Int J Clin Exp Pathol; 2015; 8(4):4132-7. PubMed ID: 26097603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BAG-1/SODD, HSP70, and HSP90 are potential prognostic markers of poor survival in node-negative breast carcinoma.
    Davidson B; Valborg Reinertsen K; Trinh D; Reed W; Bøhler PJ
    Hum Pathol; 2016 Aug; 54():64-73. PubMed ID: 27038683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of palladin is associated with disease progression in metastatic high-grade serous carcinoma.
    Davidson B; Bock AJ; Holth A; Nymoen DA
    Cytopathology; 2020 Nov; 31(6):572-578. PubMed ID: 32741023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression and clinical role of long non-coding RNA in high-grade serous carcinoma.
    Filippov-Levy N; Cohen-Schussheim H; Tropé CG; Hetland Falkenthal TE; Smith Y; Davidson B; Reich R
    Gynecol Oncol; 2018 Mar; 148(3):559-566. PubMed ID: 29310950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma.
    Vaksman O; Hetland TE; Trope' CG; Reich R; Davidson B
    Hum Pathol; 2012 Nov; 43(11):2062-9. PubMed ID: 22647351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HtrA1 expression and the prognosis of high-grade serous ovarian carcinoma: a cohort study using digital analysis.
    Gagné A; Têtu B; Orain M; Turcotte S; Plante M; Grégoire J; Renaud MC; Bairati I; Trudel D
    Diagn Pathol; 2018 Aug; 13(1):57. PubMed ID: 30131069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer.
    Baquero MT; Hanna JA; Neumeister V; Cheng H; Molinaro AM; Harris LN; Rimm DL
    Cancer; 2012 Oct; 118(19):4660-9. PubMed ID: 22359235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. miR-223 potentially targets SWI/SNF complex protein SMARCD1 in atypical proliferative serous tumor and high-grade ovarian serous carcinoma.
    Arts FA; Keogh L; Smyth P; O'Toole S; Ta R; Gleeson N; O'Leary JJ; Flavin R; Sheils O
    Hum Pathol; 2017 Dec; 70():98-104. PubMed ID: 29079174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas.
    Niu N; Shen W; Zhong Y; Bast RC; Jazaeri A; Sood AK; Liu J
    Hum Pathol; 2021 Jul; 113():20-27. PubMed ID: 33887301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma.
    Creighton CJ; Hernandez-Herrera A; Jacobsen A; Levine DA; Mankoo P; Schultz N; Du Y; Zhang Y; Larsson E; Sheridan R; Xiao W; Spellman PT; Getz G; Wheeler DA; Perou CM; Gibbs RA; Sander C; Hayes DN; Gunaratne PH;
    PLoS One; 2012; 7(3):e34546. PubMed ID: 22479643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma.
    Fritz HKM; Lindgren D; Ljungberg B; Axelson H; Dahlbäck B
    Eur J Cancer; 2014 Jul; 50(10):1758-1765. PubMed ID: 24793999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
    Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
    Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
    Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
    Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of Nestin and CD133 in serous ovarian carcinoma.
    Onisim A; Iancu M; Vlad C; Kubelac P; Fetica B; Fulop A; Achimas-Cadariu A; Achimas-Cadariu P
    J BUON; 2016; 21(5):1168-1175. PubMed ID: 27837619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.